United States Newcastle Disease Vaccine Market 2026 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Newcastle Disease Vaccine Market is growing at a CAGR of 3.6 % during the forecast period (2024-2031).

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/newcastle-disease-vaccine-market?sb

Key Development:

United States: Newcastle Disease Vaccine - Industry Developments

✅ In January 2026, researchers published promising results on a recombinant Newcastle Disease Virus (NDV) vaccine offering long-term protection in chickens, highlighting next-gen ND vaccine candidates that could transform poultry immunization strategies with sustained immunity from single doses.

✅ In January 2026, U.S. poultry and animal health experts continue to discuss deploying enhanced ND/IB vaccination protocols that bolster the innate immune system of broiler chicks, reflecting evolving immunization science and vaccine strategy optimization.

✅ In October 2025, the USDA approved an innovative recombinant Newcastle Disease vaccine developed in collaboration with academic research institutions, enhancing protection against evolving virus strains. The vaccine strengthens national poultry health programs. It supports proactive disease prevention across commercial poultry farms.

✅ In June 2025, Ceva Animal Health initiated large-scale field trials for a needle-free Newcastle Disease vaccine delivery system in the U.S., improving vaccination efficiency and reducing stress in birds. The approach enhances operational scalability. It supports modernized poultry immunization practices.

✅ In February 2025, the U.S. Department of Agriculture granted conditional clearance for a next-generation poultry vaccine platform with applications across avian viral diseases, reinforcing regulatory support for rapid vaccine deployment. The initiative strengthens outbreak preparedness. It contributes to resilient poultry biosecurity systems.

✅ In 2024, U.S. research programs advanced next-generation Newcastle Disease vaccine platforms targeting variant strains, focusing on longer immunity duration and improved immune response. These developments support sustained poultry health. They reflect ongoing innovation in avian vaccine R&D.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=newcastle-disease-vaccine-market

Japan: Newcastle Disease Vaccine - Industry Developments

✅ In September 2025, a thermostable Newcastle Disease vaccine was introduced for poultry producers in Japan, designed to improve vaccine effectiveness in regions with limited cold-chain infrastructure. The launch enhances rural vaccination coverage. It strengthens national poultry disease control efforts.

✅ In August 2025, Intervet K.K. expanded local R&D and bioprocessing investments to support next-generation Newcastle Disease vaccine development, focusing on advanced adjuvant systems. The initiative boosts domestic vaccine innovation. It reinforces Japan's livestock health ecosystem.

✅ In July 2025, Nisseiken Co., Ltd. completed the acquisition of a biotechnology startup specializing in advanced Newcastle Disease vaccine technologies, expanding its poultry vaccine portfolio. The acquisition accelerates innovation. It enhances rapid-response vaccine development capabilities.

✅ In July 2024, Vaxxinova Japan launched a combination vaccine covering Newcastle Disease, infectious bronchitis, and egg-drop syndrome, enabling broader disease protection in a single application. The product improves farm-level efficiency. It supports integrated poultry health management.

Key Players:

=> Boehringer Ingelheim, Ceva Animal Health LLC, CAVAC, GALVmed, Hester Biosciences Limited, Merck Animal Health, Elanco, Zoetis, Inc., and QYH Biotech

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/newcastle-disease-vaccine-market?sb

Key Segments:

By Type

Live Vaccines dominate the market with approximately 48% share, driven by their strong immunogenic response, long-lasting immunity, and widespread adoption in large-scale poultry vaccination programs.

Killed Vaccines account for nearly 32% share, supported by their high safety profile, stability, and suitability for booster vaccination schedules.

Thermostable Vaccines hold around 20% share, gaining traction due to their extended shelf life, reduced cold-chain dependency, and increasing use in developing and remote poultry-producing regions.

By Application

Chicken represents the largest segment with approximately 74% share, driven by the global dominance of broiler and layer production and high vaccination coverage rates.

Turkey accounts for about 18% share, supported by rising commercial turkey farming and increasing focus on disease prevention.

Others contribute roughly 8% share, including ducks, geese, and specialty poultry birds.

By Region

Asia Pacific leads the market with approximately 34% share, driven by large poultry populations, rising protein consumption, and expanding commercial poultry farming.

North America follows with around 26% share, supported by advanced vaccination infrastructure, strong biosecurity practices, and high adoption of preventive veterinary healthcare.

Europe holds nearly 22% share, driven by stringent animal health regulations and increasing demand for high-quality poultry products.

Latin America accounts for about 12% share, fueled by expanding poultry exports and improving veterinary healthcare access.

Middle East & Africa represent roughly 6% share, supported by growing poultry production and increasing awareness of disease management.

Outlook & Opportunity

The market is expected to grow steadily through 2024-2031, driven by rising demand for poultry protein, increasing incidence of avian diseases, and growing emphasis on preventive vaccination programs. Key opportunities lie in thermostable vaccine development, mass vaccination technologies, and expansion into emerging poultry markets, particularly across Asia Pacific, Latin America, and Africa.

FAQ

Q: What is the growth rate of the Newcastle Disease Vaccine Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 3.6% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.